NGM Biopharma surges on preliminary data from cancer therapy trial

NGM Biopharmaceuticals

06/09/2022 19:04

** Shares of drug developer NGM Biopharmaceuticals  NGM.O 
rise 5.6% to $15.21
    ** Co reports preliminary data from ongoing early-stage
study of its experimental cancer therapy NGM120  urn:newsml:reuters.com:*:nGNX8VSFn2
    ** Trial is testing NGM120 in patients with advanced
prostate cancer
    ** Treatment with NGM120 in the study has been
well-tolerated so far with no dose-limiting toxicities, and it
provides encouraging signals of anti-cancer activity - NGM
    ** All 6 brokerages covering the stock rate it "buy" or
higher; their median PT is $32 - Refinitiv data
    ** Including session's gain, stocks has fallen 14.12% YTD

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))